against rapidly mutating cancer cells. Known as circulating tumor cell technology (CTC), the research is led by two scientists, Dr. Daniel Haber, of Massachusetts General Hospital Cancer Center, and Dr. Mehmet Toner, of the Center for Bio Micro Electro-Mechanical Systems. Epstein's The-Foundation notes that CTC is still in the early stages